Navigation Links
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Date:8/27/2008

ties included anemia (17%), thrombocytopenia (17%), neutropenia (8%) and increased creatinine (8%).

In GIST, severe (NCI Grades 3/4) lab abnormalities (400 mg/day; 600 mg/day) -- including neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia (0%; 1%) and hepatotoxicity (6%; 8%) -- and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (e.g., pleural effusion or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain (11%; 4%), nausea (6%; 4%), diarrhea (3%; 7%) and musculoskeletal pain (6%; 1%) were reported among patients receiving Gleevec.

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Dose adjustments may be necessary due to hepatotoxicity, other nonhematologic adverse reactions, or hematologic adverse reactions. Therapy with Gleevec was discontinued for drug-related adverse reactions in 2.4% to 5% of adult patients with Ph+ CML and for adverse reactions in 5% of KIT+ GIST patients. None of the 5 patients in the ASM study discontinued Gleevec due to drug-related events or abnormal laboratory values. Complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2-3 months).

A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment.

Some GIST patients (5%) were reported to have severe gastrointestinal (GI) bleeds and/or intratumoral bleeds. GI tumor sites may have been the source of GI bleeds.

Patients
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
2. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
3. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
4. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
5. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
6. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
10. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
11. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... to offer and sell shares of its Common Stock ... concurrent underwritten public offerings.  The Series A Convertible Preferred ... Common Stock, provided that conversion will be prohibited if, ... beneficially own more than 4.99% of the Common Stock ...
(Date:9/17/2014)... and PRINCETON, N.J. , Sept. ... the pioneer in developing targeted therapeutic devices to address ... diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed today that ... & SingleCell Analysis Summit. On September 18 ... will give a presentation entitled: "Exosomes: A Multiplexed Platform ...
(Date:9/17/2014)... Ga. , Sept. 17, 2014  MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today the publication of another peer-reviewed clinical study. ... A Multi-center Randomized Controlled Clinical Trial Evaluating ... Amnion/Chorion Membrane Allografts and Multi-layer Compression Therapy vs. ...
(Date:9/17/2014)... 2014 JH Technologies announces ... in Irvine. JH Technologies, a leader in sales ... announced an expanded partnership with Leica Microsystems into the ... image analysis solutions will be featured at the grand ... new showroom facility is located within the JH Technologies ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3
...   Hospitals, health systems to benefit,from ... and other,performance management solutions Elsevier ... products,and services, has struck an exclusive partnership with ... learning solutions for process,improvement. Elsevier will market ...
... carbon, has the potential to make consumer electronic devices ... shrinking scale of electronics, also make graphene difficult to ... In September 2010, a UCLA research team ... and were able to fabricate graphene transistors with unparalleled ...
... 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ) ... agreements with various institutional investors and its CEO for ... in a registered direct offering at $8.85 per share, ... of the offering, before deducting expenses, are expected to ...
Cached Biology Technology:Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 2Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2Pharmacyclics Announces Results of Registered Direct Offering 2Pharmacyclics Announces Results of Registered Direct Offering 3
(Date:9/16/2014)... sick can take up residence in and on the ... troublesome symptom, according to new research at Washington University ... average, healthy individuals carry about five types of viruses ... BioMed Central Biology . The study is the first ... healthy people. , The research was conducted as ...
(Date:9/16/2014)... chunk of rock hit the Yukatan peninsula near the site ... 100 teratons of TNT. It left a crater more than ... and volcanism are widely accepted to have wiped out the ... But what happened to the plants on which the dinosaurs ... University of Arizona reveals that the meteorite impact that spelled ...
(Date:9/16/2014)... would likely increase oil sands extraction, according to 26 ... organization Near Zero. The results are detailed in the ... supporters and opponents of the pipeline. , ... significantly higher greenhouse gas emissions, with the exact amount ... report examines three main scenarios discussed by participants in ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... release is available in German . , ... cannot tell us about their cognitive skills or give ... in Svante Paabo,s team at the Max Planck Institute ... DNA of Neanderthals, they have made some new and ...
... Low-density lipoprotein (LDL), a transporter of cholesterol, may also ... according to a report published online this week in ... LDL (nLDL) and the vascular endothelial growth factor receptor ... vessel formation. LDL is responsible for transporting cholesterol ...
... spot for Botswana, developed while reading the best-selling #1 ... chance to do any sleuthing of their own in ... Illinois scientist Karen Chapman-Novakofski acquired a Batswana doctoral student ... and nutrition of that country,s elderly. "In Botswana, ...
Cached Biology News:Red hair and freckles... 2U of I scientist does nutritional detective work in Botswana 2U of I scientist does nutritional detective work in Botswana 3
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... be used for the identification of potential biomarkers ... and other diseases. Due to the fact that ... it provides an attractive alternative to blood plasma ... ProteoSpin Urine Protein Concentration Micro Kit provides ...
... forces with the Mickle Laboratory Engineering Company ... This tissue sectioning system has been designed ... experiments and to be especially applicable to ... or from small organs. Its special features ...
Biology Products: